We are not surprised by the latest developments surrounding the current crop of vaccines and the problems that have arisen, especially with regard to AstraZeneca. Since April 2020, we have repeatedly pointed out shortcomings in the design of the pivotal study, the results of the efficacy study and even fundamental design flaws in the vaccine.